Valuation: NEOVACS

Market Cap 4.09K 4.67K 3.77K 3.5K 6.64K 445K 6.73K 45.08K 17.55K 219K 17.53K 17.15K 758K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -229K -185K -172K -326K -21.89M -331K -2.22M -862K -10.75M -862K -843K -37.26M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day-9.62%
1 week+9.27%
Current month+9.27%
1 month-39.90%
3 months-79.97%
6 months-98.50%
Current year-98.62%
1 week 1.02
Extreme 1.015
1.68
1 month 1.02
Extreme 1.015
4
Current year 1.02
Extreme 1.015
267
1 year 1.02
Extreme 1.015
22,000
3 years 1.02
Extreme 1.015
1,000,000
5 years 1.02
Extreme 1.015
1,000,000
10 years 1.02
Extreme 1.015
1,000,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Chairman - -
Director/Board Member - 01/05/2020
Date Insider Type Main position Quantity % Market Cap.
27/02/21Sell

Chief Executive Officer

2,505,144 1.3796%
23/02/21Sell

Chief Executive Officer

6,391,053 3.5196%
23/02/21Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-9.62%+9.27%-99.99%-100.00% 242K
+0.12%+6.41%+4.09%+10.63% 50.25B
+0.40%-1.37%+401.69%+625.15% 40.39B
-0.52%+6.57%+25.41%-5.37% 34.38B
+3.97%+6.71%+26.06%+63.36% 34.4B
-4.19%-1.84%+3.76%+32.17% 26.32B
-2.40%+1.60% - - 16.64B
+1.34%+5.68%+75.77%+141.51% 16.14B
+1.25%+1.49%+15.43%+22.63% 13.71B
+1.69%+3.09%+93.44%+99.19% 13.75B
Average -0.79%+2.32%+60.63%+98.81% 24.6B
Weighted average by Cap. +0.22%+4.03%+91.64%+142.08%

Financials

2023 2024
Net sales 533K 609K 491K 456K 866K 58.1M 878K 5.88M 2.29M 28.52M 2.29M 2.24M 98.87M 434K 495K 400K 371K 705K 47.26M 714K 4.78M 1.86M 23.2M 1.86M 1.82M 80.43M
Net income -8.74M -9.98M -8.05M -7.48M -14.2M -952M -14.39M -96.4M -37.52M -467M -37.49M -36.67M -1.62B -32.91M -37.58M -30.32M -28.14M -53.44M -3.58B -54.16M -363M -141M -1.76B -141M -138M -6.1B
Net Debt -237K -270K -218K -202K -384K -25.76M -389K -2.61M -1.01M -12.64M -1.01M -992K -43.84M -205K -234K -189K -175K -333K -22.34M -337K -2.26M -880K -10.96M -879K -860K -38.01M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
07/07/26 1.202 -9.62% 5,049
06/07/26 €1.330 +3.91% 9,706
03/07/26 €1.280 -22.89% 14,311
02/07/26 €1.660 +26.72% 7,626
01/07/26 €1.310 +19.09% 15,465
  1. Stock Market
  2. Stocks
  3. ALNEV Stock